Lina E Aguirre1, Georgia Colleluori1, Kenneth E Fowler1, Irum Zeb Jan1, Kenneth Villareal2, Clifford Qualls1, David Robbins1, Dennis T Villareal1, Reina Armamento-Villareal3. 1. New Mexico VA Health Care SystemAlbuquerque, New Mexico, USABiomedical Research Institute of New MexicoAlbuquerque, New Mexico, USAUniversity of New Mexico School of MedicineAlbuquerque, New Mexico, USAUniversity Campus Bio-MedicoRome, ItalyMichael E DeBakey VA Medical Center2002 Holcombe Boulevard, Houston, Texas 77030, USABaylor College of MedicineHouston, Texas, USA New Mexico VA Health Care SystemAlbuquerque, New Mexico, USABiomedical Research Institute of New MexicoAlbuquerque, New Mexico, USAUniversity of New Mexico School of MedicineAlbuquerque, New Mexico, USAUniversity Campus Bio-MedicoRome, ItalyMichael E DeBakey VA Medical Center2002 Holcombe Boulevard, Houston, Texas 77030, USABaylor College of MedicineHouston, Texas, USA. 2. New Mexico VA Health Care SystemAlbuquerque, New Mexico, USABiomedical Research Institute of New MexicoAlbuquerque, New Mexico, USAUniversity of New Mexico School of MedicineAlbuquerque, New Mexico, USAUniversity Campus Bio-MedicoRome, ItalyMichael E DeBakey VA Medical Center2002 Holcombe Boulevard, Houston, Texas 77030, USABaylor College of MedicineHouston, Texas, USA. 3. New Mexico VA Health Care SystemAlbuquerque, New Mexico, USABiomedical Research Institute of New MexicoAlbuquerque, New Mexico, USAUniversity of New Mexico School of MedicineAlbuquerque, New Mexico, USAUniversity Campus Bio-MedicoRome, ItalyMichael E DeBakey VA Medical Center2002 Holcombe Boulevard, Houston, Texas 77030, USABaylor College of MedicineHouston, Texas, USA New Mexico VA Health Care SystemAlbuquerque, New Mexico, USABiomedical Research Institute of New MexicoAlbuquerque, New Mexico, USAUniversity of New Mexico School of MedicineAlbuquerque, New Mexico, USAUniversity Campus Bio-MedicoRome, ItalyMichael E DeBakey VA Medical Center2002 Holcombe Boulevard, Houston, Texas 77030, USABaylor College of MedicineHouston, Texas, USA reina.villareal@bcm.edu.
Abstract
OBJECTIVE: Because the aromatase enzyme catalyzes the conversion of testosterone to estradiol (E2), the activity of this enzyme could be important in the musculoskeletal health of men with low testosterone. The objective of the present study is to determine the influence of aromatase activity on the bone mineral density (BMD) and body composition of patients with hypogonadism. DESIGN: Cross-sectional study. METHODS: The baseline data of 90 patients between 40 and 74 years old who participated in a genetic study of response to testosterone therapy in men with low testosterone (i.e., <300 ng/dl) were analyzed. BMD and body composition were measured by dual-energy X-ray absorptiometry. Serum testosterone was measured by automated immunoassay, E2 was measured by ultrasensitive enzyme immunoassay, and sex hormone-binding globulin was measured by enzyme immunoassay. RESULTS: Men in the highest tertile of E2 to testosterone ratio (E2:T) had the highest spine BMD (P ≤ 0.037), highest truncal fat (P=0.046), and lowest truncal lean body mass (P=0.045). A similar pattern was observed in the upper extremities; that is, fat mass significantly increased (P=0.047), whereas lean mass significantly decreased (P=0.034) with increasing E2:T tertiles. CONCLUSION: The present findings suggest that in men with hypogonadism, aromatase activity could be an important determinant of musculoskeletal health. Men with high aromatase activity are able to maintain a higher BMD despite low circulating testosterone, but they have lower lean and higher truncal fat mass as compared to those with lower aromatase activity.
OBJECTIVE: Because the aromatase enzyme catalyzes the conversion of testosterone to estradiol (E2), the activity of this enzyme could be important in the musculoskeletal health of men with low testosterone. The objective of the present study is to determine the influence of aromatase activity on the bone mineral density (BMD) and body composition of patients with hypogonadism. DESIGN: Cross-sectional study. METHODS: The baseline data of 90 patients between 40 and 74 years old who participated in a genetic study of response to testosterone therapy in men with low testosterone (i.e., <300 ng/dl) were analyzed. BMD and body composition were measured by dual-energy X-ray absorptiometry. Serum testosterone was measured by automated immunoassay, E2 was measured by ultrasensitive enzyme immunoassay, and sex hormone-binding globulin was measured by enzyme immunoassay. RESULTS:Men in the highest tertile of E2 to testosterone ratio (E2:T) had the highest spine BMD (P ≤ 0.037), highest truncal fat (P=0.046), and lowest truncal lean body mass (P=0.045). A similar pattern was observed in the upper extremities; that is, fat mass significantly increased (P=0.047), whereas lean mass significantly decreased (P=0.034) with increasing E2:T tertiles. CONCLUSION: The present findings suggest that in men with hypogonadism, aromatase activity could be an important determinant of musculoskeletal health. Men with high aromatase activity are able to maintain a higher BMD despite low circulating testosterone, but they have lower lean and higher truncal fat mass as compared to those with lower aromatase activity.
Authors: E Barrett-Connor; J E Mueller; D G von Mühlen; G A Laughlin; D L Schneider; D J Sartoris Journal: J Clin Endocrinol Metab Date: 2000-01 Impact factor: 5.958
Authors: C Carani; K Qin; M Simoni; M Faustini-Fustini; S Serpente; J Boyd; K S Korach; E R Simpson Journal: N Engl J Med Date: 1997-07-10 Impact factor: 91.245
Authors: S Vandewalle; Y Taes; T Fiers; K Toye; E Van Caenegem; I Roggen; J De Schepper; J-M Kaufman Journal: J Clin Endocrinol Metab Date: 2014-03-26 Impact factor: 5.958
Authors: Judith S Brand; Maroeska M Rovers; Bu B Yeap; Harald J Schneider; Tomi-Pekka Tuomainen; Robin Haring; Giovanni Corona; Altan Onat; Marcello Maggio; Claude Bouchard; Peter C Y Tong; Richard Y T Chen; Masahiro Akishita; Jourik A Gietema; Marie-Hélène Gannagé-Yared; Anna-Lena Undén; Aarno Hautanen; Nicolai P Goncharov; Philip Kumanov; S A Paul Chubb; Osvaldo P Almeida; Hans-Ulrich Wittchen; Jens Klotsche; Henri Wallaschofski; Henry Völzke; Jussi Kauhanen; Jukka T Salonen; Luigi Ferrucci; Yvonne T van der Schouw Journal: PLoS One Date: 2014-07-14 Impact factor: 3.240
Authors: Georgia Colleluori; Lina Aguirre; Richard Dorin; David Robbins; Dean Blevins; Yoann Barnouin; Rui Chen; Clifford Qualls; Dennis T Villareal; Reina Armamento-Villareal Journal: Bone Date: 2017-03-16 Impact factor: 4.398
Authors: Elliot Ballato; F N U Deepika; Vittoria Russo; Alcibiades Fleires-Gutiérrez; Georgia Colleluori; Virginia Fuenmayor; Rui Chen; Dennis T Villareal; Clifford Qualls; Reina Armamento-Villareal Journal: Calcif Tissue Int Date: 2022-06-04 Impact factor: 4.000
Authors: Lina E Aguirre; Georgia Colleluori; Richard Dorin; David Robbins; Rui Chen; Bryan Jiang; Clifford Qualls; Dennis T Villareal; Reina Armamento-Villareal Journal: Calcif Tissue Int Date: 2017-08-30 Impact factor: 4.333
Authors: N Tahani; L Nieddu; G Prossomariti; M Spaziani; S Granato; F Carlomagno; A Anzuini; A Lenzi; A F Radicioni; E Romagnoli Journal: Endocrine Date: 2018-04-25 Impact factor: 3.633